RAM
KROS icon

Readystate Asset Management’s Keros Therapeutics KROS Stock Holding History

Readystate Asset Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-25,523
Closed -$404K – 678
2024
Q4 		$404K Buy
25,523
+20,920
+454% +$1.09M 0.01% 518
2024
Q3 		$267K Sell
4,603
-109,220
-96% -$5.39M 0.01% 510
2024
Q2 		$5.2M Buy
113,823
+19,450
+21% +$1.05M 0.17% 105
2024
Q1 		$6.25M Buy
+94,373
New +$5.6M 0.09% 324

Other funds holding KROS

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Readystate Asset Management's KROS Position: Q1 2025 in Review

Readystate Asset Management sold out of Keros Therapeutics (KROS) in Q1 2025, closing a stake of 25,523 shares — an estimated $404K sold.

Readystate Asset Management first reported a position in KROS in Q1 2024 and held it in 4 quarters. The position peaked at $6.25M in Q1 2024. 156 funds tracked by Wall St. Rank hold KROS as of Q1 2025.

  • Readystate Asset Management reported no remaining Keros Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Readystate Asset Management sold 25,523 Keros Therapeutics shares in Q1 2025, an estimated $404K.
  • Readystate Asset Management first reported a position in Keros Therapeutics in Q1 2024 and held it in 4 quarters.
  • Readystate Asset Management's Keros Therapeutics position peaked at $6.25M in Q1 2024.
  • 156 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2025.

Based on Readystate Asset Management's 13F filing for Q1 2025, filed 6 May 2025.